Companies › Shenzhen Xinhe Biomedical
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Oct 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XH001 Injection Personalized mRNA neoantigen cancer vaccine | – | Phase 1 | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer); Gastrointestinal Cancer; Advanced Gastric Cancer | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07329894 | XH001 Injection | Phase 1 | Gastrointestinal Cancer | Oncology | Aug 2027 |
| NCT07298200 | XH001 Injection | Phase 1 | Advanced Gastric Cancer | Oncology | Jun 2028 |
| NCT07594964 | XH001 Injection | Phase 1 | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) | Oncology | Oct 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.